Persistent Antiphospholipid Antibodies Are Not Associated With Worse Clinical Outcomes in a Prospective Cohort of Hospitalised Patients With SARS-CoV-2 Infection

Persistent Antiphospholipid Antibodies Are Not Associated With Worse Clinical Outcomes in a Prospective Cohort of Hospitalised Patients With SARS-CoV-2 Infection

ObjectivePatients with COVID-19 presented with an elevated prevalence of antiphospholipid antibodies (aPL) but the relationship with thrombosis is controversial. We analysed the persistence of aPL and their association with the clinical outcomes during hospitalisation in a cohort of COVID-19 patient...

Full description

Bibliographic Details
Main Authors: Gerard Espinosa, Carles Zamora-Martínez, Albert Pérez-Isidro, Daniela Neto, Luz Yadira Bravo-Gallego, Sergio Prieto-González, Odette Viñas, Ana Belen Moreno-Castaño, Estíbaliz Ruiz-Ortiz, Ricard Cervera, The COVAPS-CLINIC Study Group Investigators, Alex Almuedo, Giuseppe Barilaro, Daniel Camprubí, Júlia Calvo, Aina Capdevila-Reniu, Irene Carbonell, Georgina Espígol-Frigolé, Cristina Gabara, Priscila Giavedoni, Ignacio Grafia, Andrea Ladino, Gema Maria Lledó-Ibáñez, Ana Matas-García, Pere Millat, Pedro Juan Moreno, Magdalena Muelas, José Muñoz, José Naval, Joan Padrosa, Martina Pellicé, María Jesús Pinazo, Roberto Ríos-Garcés, Natalia Rodríguez, Olga Rodríguez-Núñez, Estibaliz Ruiz-Ortiz, Ruth Sotil, Adrià Tomé, Helena Ventosa
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Immunology
Subjects:
COVID - 19
antiphospholipid antibodies
antiphospholipid syndrome - immunology
diagnosis
thrombosis - immunology
persistence
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.911979/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.911979/full

Similar Items